BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $2.10 billion. The enterprise value is $2.67 billion.
Important Dates
The last earnings date was Monday, May 5, 2025, before market open.
| Earnings Date | May 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 209.21 million shares outstanding. The number of shares has increased by 5.50% in one year.
| Current Share Class | 209.21M |
| Shares Outstanding | 209.21M |
| Shares Change (YoY) | +5.50% |
| Shares Change (QoQ) | +3.80% |
| Owned by Insiders (%) | 1.04% |
| Owned by Institutions (%) | 75.55% |
| Float | 195.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 33.60 |
| PS Ratio | 4.23 |
| Forward PS | 3.58 |
| PB Ratio | -4.51 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.30 |
| EV / EBITDA | 70.43 |
| EV / EBIT | 77.51 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | 22.20 |
| Debt / FCF | n/a |
| Interest Coverage | 0.35 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 5.80% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | $868,078 |
| Profits Per Employee | -$92,190 |
| Employee Count | 580 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BCRX has paid $2.29 million in taxes.
| Income Tax | 2.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +90.51% in the last 52 weeks. The beta is 1.08, so BCRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +90.51% |
| 50-Day Moving Average | 7.90 |
| 200-Day Moving Average | 7.83 |
| Relative Strength Index (RSI) | 67.21 |
| Average Volume (20 Days) | 5,402,670 |
Short Selling Information
The latest short interest is 20.44 million, so 9.77% of the outstanding shares have been sold short.
| Short Interest | 20.44M |
| Short Previous Month | 20.73M |
| Short % of Shares Out | 9.77% |
| Short % of Float | 10.47% |
| Short Ratio (days to cover) | 6.59 |
Income Statement
In the last 12 months, BCRX had revenue of $503.49 million and -$53.47 million in losses. Loss per share was -$0.26.
| Revenue | 503.49M |
| Gross Profit | 323.48M |
| Operating Income | 34.44M |
| Pretax Income | -146.50M |
| Net Income | -53.47M |
| EBITDA | 37.90M |
| EBIT | 34.44M |
| Loss Per Share | -$0.26 |
Full Income StatementBalance Sheet
The company has $320.85 million in cash and $841.42 million in debt, giving a net cash position of -$520.57 million or -$2.49 per share.
| Cash & Cash Equivalents | 320.85M |
| Total Debt | 841.42M |
| Net Cash | -520.57M |
| Net Cash Per Share | -$2.49 |
| Equity (Book Value) | -475.93M |
| Book Value Per Share | -2.28 |
| Working Capital | n/a |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 64.25%, with operating and profit margins of 6.84% and -10.62%.
| Gross Margin | 64.25% |
| Operating Margin | 6.84% |
| Pretax Margin | -10.17% |
| Profit Margin | -10.62% |
| EBITDA Margin | 7.53% |
| EBIT Margin | 6.84% |
| FCF Margin | n/a |